The Hypertension Optimal Treatment (HOT) study was designed to define the optimal target blood pressure (BP) during antihypertensive treatment. 1 The background is that hypertensive patients remain at a greater risk for developing cardiovascular diseases despite antihypertensive treatment. 2 The explanation could be that the BP is not lowered to normotensive levels. 3 On the other hand concerns have been expressed that too vigorous BP reduction, especially in patients with ischaemic heart disease, may be associated with increased cardiovascular risk, the J-curve concept. 4, 5 In the HOT study close to 19 000 patients with hypertension were randomised to three levels of target BP during treatment: р90 mm Hg, р85 mm Hg or р80 mm Hg. Antihypertensive treatment was initiated with the calcium antagonist felodipine. If needed an angiotensin-converting enzyme (ACE) inhibitor or a ␤-blocker was added, and finally a thiazide diuretic. Doses were increased stepwise when needed for reaching the target BP.
The first impressive finding is a very pronounced reduction of BP ranging from 20-24 mm Hg in diastolic BP and from 26-30 mm Hg in systolic BP depending on the target BP to which the patients were randomised.
The next important finding is that the rates of cardiovascular morbidity and mortality in the HOT study were much lower than expected from the results of earlier trials. 6 This finding is most likely related to the considerable fall in BP. The study shows that the maximal protection, ie, the lowest rate of major cardiovascular events is obtained at a BP level around 140/85 mm Hg.
There is one disappointment: the BP level in the three randomised target groups came close to each other with a large overlap between the groups. This makes it difficult to disclose any significant differences in the end-point rate betwen the three target BP groups. The number of major cardiovascular events were equal in the three groups; the only difference of borderline significance was a 38% reduction in myocardial infarction in the target group р80 mm Hg as compared to the target group р90 mm Hg. As a consequence emphasis is put on an analysis relating the achieved BP level to the end-point rate. This analysis shows that the minimum rate of major cardiovascular event is obtained at a BP of 138 mm Hg systolic and 83 mm Hg diastolic. The strength of this conclusion is somewhat reduced by the fact that it is not reached in terms of an analysis related to randomisation.
In the subgroup of 1500 patients with diabetes mellitus at baseline, results are clear-cut: in the group randomised to р80 mm Hg the rate of major cardiovascular events is half of that in the target group р90 mm Hg.
The results in the subgroup of 3000 patients with ischaemic heart disease at baseline showed a tendency towards fewer major cardiovascular events in relation to the three target groups, to be only significant for stroke, a 43% reduction in the stroke р80 mm Hg target group as compared to the р90 mm Hg target group.
A very important finding is no significant J-curve in the full range of achieved BP down to a level of 120/70 mm Hg, either in the group as a whole or in the group of 3000 patients with ischaemic heart disease. This means that within the range of obtainable BPs in hypertensive patients no signs of J-curve are seen in a large prospective study.
The second aim of the HOT study was to define whether the addition of a low dose of acetylsalicylic acid (ASA: 75 mg once a day) to antihypertensive treatment reduces the rate of major cardiovascular events. The HOT study is the first primary prevention study of ASA in patients with hypertension. The results show that ASA reduces major cardiovascular events by 15% and myocardial infarction by 36% with no effect on stroke. There was no increase in fatal bleeding complications or intracerebral bleeding, but the incidence of non-fatal major bleeding was nearly twice as high in the ASA group as compared to the placebo group. It is noteworthy that the results are obtained in patients with well controlled hypertension.
What is the impact of the HOT study on hypertension management? (1 
